19/02/2024 16:56

Cochlear (COH) $327.82

COH -2.01%: the hearing implants company’s 1H was largely pre-announced at a trading update last week, Cochlear pulled back from all-time highs hit on Friday on slight cracks showing in the numbers.

Read more

09/02/2024 09:30

Cochlear Ltd (COH) $304.74

We discussed COH earlier in the week after it was downgraded to a “Sell” by UBS who made some interesting points around the potential for Moderna getting a vaccine approved to treat ~20% of child deafness.

Read more

07/02/2024 09:24

Cochlear Ltd (COH) $287.29

COH uncharacteristically fell almost 7% on Tuesday after influential UBS downgraded the stock to a sell on competition fears after the stock's ~50% advance since 2023. Their main discussion reminded us of the Ozempic et al. fears that sent ResMed (RMD) tumbling in August/September of last year0

Read more

30/11/2023 09:11

Cochlear Ltd (COH) $267.00

The Healthcare Sector has embraced the advance by bonds through November, and we anticipate this improvement over the last 5-weeks will continue into 2024. However, it's still likely to be patchy, as we’ve witnessed through most of 2023. Our preferred scenario is a “risk on” style Christmas rally that will see some less popular names enjoy a rare period of outperformance.

Read more

07/11/2023 09:11

Cochlear Ltd (COH) $US247.29

COH is up +21% so far this year, but interestingly, it hasn’t caught our attention as much as more battered names over the last week's turnaround – one week doesn’t make a summer. If we are correct and bond yields drift/fall into Christmas we believe the best performance within the Healthcare Secxtor will be enjoyed by stocks that really struggled in the first three quarters.

Read more

13/10/2023 09:41

Cochlear Ltd (COH) $US257.35

COH has bucked the sector trend, rising +26% in 2023 after reporting strongly in August – FY23 sales revenue beat expectations by ~6% and FY24 earnings guidance was very strong, looking for growth of 16-23% YoY. This is a great company doing well, but it’s not cheap, leaving little room for error as investors seek refuge in the perceived pocket of safety amongst the healthcare debris.

Read more

31/08/2023 09:41

Cochlear Ltd (COH) $273.26

Hearing implant manufacturer COH delivered FY23 sales revenue that was 6% ahead of consensus, although underlying NPAT of $305m (+14% CC) was in line. Also, FY24 guidance was for underlying NPAT to increase 16-23% YoY, the result was firmly embraced by the market as it searches for “safe” options in the embattled Healthcare Sector. This is a case of a good company but a stock that we believe is arguably fully valued trading on a Est P/E of 48.8x for FY24.

Read more

15/06/2023 09:21

Cochlear Ltd (COH) $237.47

COH has performed strongly through 2023 and even after it slipped back under $240 it’s up over +16% year to date. We liked the hearing aid operators’ 1H23 result with revenue of $892m beating expectations while Net Profit After Tax (NPAT) of $142m was 8% ahead of consensus, plus they rewarded loyal shareholders with a supportive buy-back as they deploy cash on their balance sheet.

Read more

17/03/2023 09:11

Cochlear Ltd (COH) $230.25

Hearing aid company Cochlear has tread water for the last few years which in comparison to many of its growth peers is a great result when interest rates soared higher. We particularly liked their 1H23 result with revenue of $892m, above the $850m expected while Net Profit After Tax (NPAT) of $142m was 8% ahead of consensus.

Read more

15/02/2023 16:57

Cochlear (COH) $225.28

COH +7.72%: A good result here with 1H23 revenue of $892m, above the $850m expected while Net Profit After Tax (NPAT) of $142m was 8% ahead of consensus.

Read more